Margret Jandl
Overview
Explore the profile of Margret Jandl including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
32
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bal C, Stoshikj S, Renner A, Milger K, Skowasch D, Schulz C, et al.
Pulmonology
. 2025 Feb;
31(1):2460868.
PMID: 39945136
Introduction: Previous studies of anti-IL-5/IL-5(R) therapies in severe asthma found that response was mainly predicted by indicators of good baseline disease control. However, long-term response predictors remain unclear. Methods: Responders...
2.
Biener L, Stoshikj S, Brugger J, Krall C, Buhl R, Hamelmann E, et al.
J Allergy Clin Immunol Pract
. 2025 Feb;
PMID: 39900240
Background: Patients with asthma with >10 pack-years are frequently excluded from asthma trials. Little is known about how smoking affects their characteristics and therefore may impact treatment choices. Objective: To...
3.
Stoshikj S, Biener L, Renner A, Bal C, Brugger J, Krall C, et al.
J Allergy Clin Immunol Pract
. 2025 Jan;
PMID: 39800060
Background: Clinical studies of biologics in severe asthma exclude smokers or ex-smokers (ExS) with over 10 pack-years (py). Thus, the effectiveness of this therapy in ExS with severe asthma is...
4.
Puschner F, Schiller J, Urbanski-Rini D, Scholl K, Bock A, Jandl M, et al.
Pneumologie
. 2024 Aug;
PMID: 39208875
Background: COPD is one of the most common causes of death in Europe, and is associated with a high exacerbation and hospitalization rate as well as high medical costs. The...
5.
Bal C, Stoshikj S, Milger K, Skowasch D, Gappa M, Koerner-Rettberg C, et al.
Allergy
. 2024 Jun;
79(11):3133-3138.
PMID: 38864229
No abstract available.
6.
Hinze C, Ehmann R, Jandl M, Milger K, Schmidt O, Schulz C, et al.
ERJ Open Res
. 2024 Apr;
10(2).
PMID: 38590938
https://bit.ly/3SSPX1C.
7.
Suhling H, Skowasch D, Bergmann K, Mummler C, Buhl R, Ehmann R, et al.
World Allergy Organ J
. 2023 Nov;
16(12):100844.
PMID: 38033455
Background: For therapy of severe asthma 5 monoclonal antibodies have been available in Germany up to November 2022, but no clear rules exist on choice of initial therapy, assessment of...
8.
Martinez F, Criner G, Gessner C, Jandl M, Scherbovsky F, Shinkai M, et al.
Am J Respir Crit Care Med
. 2023 Jul;
208(4):417-427.
PMID: 37411039
CFTR (cystic fibrosis transmembrane conductance regulator) dysfunction is associated with mucus accumulation and worsening chronic obstructive pulmonary disease (COPD) symptoms. The aim of this phase IIb dose-finding study was to...
9.
Bal C, Pohl W, Milger K, Skowasch D, Schulz C, Gappa M, et al.
J Allergy Clin Immunol Pract
. 2023 Jul;
11(11):3417-3424.e3.
PMID: 37406803
Background: Asthma is increasingly recognized as heterogeneous, characterized by different endotypes, with obesity not only a distinct phenotype but a risk factor for severe asthma. Objective: We sought to understand...
10.
Panettieri Jr R, Welte T, Shenoy K, Korn S, Jandl M, Kerwin E, et al.
J Asthma Allergy
. 2020 Feb;
13:115-126.
PMID: 32110060
Objective: In the SOLANA trial, we sought to physiologically characterize benralizumab's onset of effect and maintenance of that effect for patients with severe eosinophilic asthma. Methods: SOLANA (NCT02869438) was a...